Comparing life sciences IP in Brazil and the US

Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead awarded $30m over counterfeit HIV drug scheme

26 November 2024 Wholesaler ‘bought nearly 17,000 bottles of fake Gilead drugs’ | US government says defendant sentenced in September should pay company for lost profits.

Americas

‘We took Ravgen head-on’: How we won zero-damages and others didn't

14 November 2024 Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Comparing life sciences IP in Brazil and the US

More on this story

Editor's picks

Editor's picks

More features